In this study among men who underwent radical prostatectomy (RP), African American men (AAM) were 28% more likely to develop recurrent disease compared with Caucasian men (CM). However, among those who had nonmetastatic, castrationresistant prostate cancer (CRPC), race did not predict metastases or overall survival. Whether race predicts metastases among men who receive androgen-deprivation therapy (ADT) after a biochemical recurrence (BCR) (ie, before CRPC but after BCR) is untested.
INTRODUCTION
African American men (AAM) have a higher risk of prostate cancer (PC) and PC-specific mortality (PCSM) than Caucasian men (CM). [1] [2] [3] [4] The exact steps in PC biology that result in PC death (ie, initiation, progression to clinically detectable disease, failure after initial treatment, failure after subsequent therapy, metastases, etc) and are influenced by race are unclear. For example, we previously demonstrated that, at the time of biopsy, AAM have a higher risk of PC and have particularly aggressive PC. 5 In contrast, among men who underwent radical prostatectomy (RP), we recently demonstrated that AAM had a higher risk of recurrence but had similar risks of progression to metastases and PC death. 6 Because androgen-deprivation therapy (ADT) is used routinely to treat advanced and especially metastatic PC, it is rare that a patient dies of PC without first receiving ADT. Therefore, disease progression (a rising prostate-specific antigen [PSA] level) despite the receipt of ADT to castrate levels results in advanced disease known as castration-resistant PC (CRPC), with or without metastasis. Despite many studies examining outcomes after primary therapy (ie, surgery or
Cancer February 1, 2019 radiation), it is notable that no prior study to date has examined whether, compared with CM, AAM are at higher risk of CRPC after the initiation of ADT.
To address this gap in the literature, using an equal-access setting of care (ie, multiple Veterans Affairs [VA] medical centers), we investigated whether race was associated with distant metastasis among men who received ADT for a biochemical recurrence (BCR) that developed after they underwent RP. In addition, we tested whether variables associated with distant metastases differed between AAM and CM. We hypothesized that race would be associated with distant metastases or other adverse outcomes and that certain variables associated with distant metastases would differ between AAM and CM.
MATERIALS AND METHODS

Patient Population
After receiving Institutional Review Board approval (VA Medical Center, Durham, NC), data from patients who underwent RP from 1988 to 2015 were combined in the Shared Equal-Access Regional Cancer Hospital (SEARCH) database. SEARCH is composed of 6 surgical sites (San Diego, West Los Angeles, and Palo Alto, California; Augusta, Georgia; and Durham and Asheville, North Carolina) and includes information on demographic and clinicopathologic variables, secondary treatments, and survival data.
Of 5515 patients in the SEARCH database, 1984 (36%) had a BCR during follow-up, defined as 2 PSA levels of 0.2 ng/mL or 1 PSA level >0.2 ng/mL after RP, or secondary treatment for a rising PSA level. Of the patients who developed a BCR, 856 (43%) went on to receive ADT after BCR. We excluded patients who developed metastases before receiving ADT (n = 105) and those of other or missing race (n = 24). Thus, after excluding men who did not develop recurrent disease or receive ADT, those who had metastases at the time of ADT, and those of other races, there were 727 eligible men. Among these, n = 132 were missing at least 1 of the covariates described below, resulting in a study cohort of 595 men (Fig. 1) . It is noteworthy that AAM were less likely to be missing covariates compared with CM (10% vs 23%, respectively; P < .001).
Study Outcomes
CRPC was defined as a PSA rise ≥2 ng/mL and ≥25% from the post-ADT nadir while being castrate. Castration was defined as a testosterone level <50 ng/dL, bilateral orchiectomy, or continuous receipt of luteinizing hormone-releasing hormone agonist or antagonist. All imaging was done at the discretion of the treating physician. Imaging reports (bone scan, magnetic resonance imaging, computed tomography, x-ray) after surgery were assessed by trained personnel to determine the development of metastases. PCSM was defined as progressive, metastatic disease after hormone therapy with no other obvious cause of death. Mortality was determined from the electronic medical records.
Statistical Analysis
Variables were compared between AAM and CM using the rank-sum test for continuous variables and the chisquare test or the Fisher exact test (for any variable with an expected cell count <5) for categorical variables.
Kaplan-Meier estimates stratified by race were graphed for each of the outcomes (the time from ADT to metastasis, CRPC, all-cause mortality [ACM], and PCSM). The difference in survival between AAM and CM for each outcome was tested using the log-rank test. Cox proportional-hazards models were used to test the association between race (African American vs Caucasian) and time from ADT to each outcome. 
RESULTS
Patient Characteristics
Our cohort consisted of 354 CM (59%) and 241 AAM (41%) ( Table 1) . Compared with CM, AAM were younger at ADT (median age, 63 vs 67 years; P < .001), had received ADT in a more recent year (median, 2008 vs 2006; P = .003), fewer had pathologic grade group 5 (12% vs 20%; P = .015), and fewer had extracapsular Cancer February 1, 2019 extension (38% vs 48%; P = .025). However, there were no statistically significant differences between any other characteristics, including PSA and PSADT at ADT.
Survival Outcomes
During a median follow-up of 66 months after ADT, there were 39, 40, 76, and 25 AAM who developed metastasis, developed CRPC, died from any cause, and died from PC, respectively; whereas 63, 68, 146, and 44 CM developed metastasis, developed CRPC, died from any cause, and died from PC, respectively. Follow-up was similar in AAM and CM (P = .77). The Kaplan-Meier graph (Figs. 2-5) indicate similar times to metastasis (log-rank P = .70), CRPC (P = .50), ACM (P = .14), and PCSM (P = .54) between AAM and CM. On both univariable and multivariable analysis, there was no association between race and any of the outcomes (all P. ≥ .14) ( Table 2 ). Although we adjusted for grade group, we noted a higher rate of pathologic grade group 4 and 5 among CM. Given the strong link between grade group and poor outcome, we performed a post hoc stratification by grade group (grade group 1-3 vs 4-5). Within both strata, no associations remained between race and CRPC, overall survival, or PCSM (all P > .05). Moreover, there was no interaction between race and pathologic grade group to predict CRPC, overall survival, or PCSM (all P interaction > .05). Race had a borderline association (although it was not statistically significant) with a higher risk of metastasis with grade group 1 through 3 (hazard ratio, 1.86; 95% confidence interval, 0.99-3.51; P = .054), but there was no association in grade group 4 and 5 (hazard ratio, 0.48; 95% confidence interval, 0.19-1.21; P = .12; P interaction = .03). However, these models only had 54 and 48 events, respectively, and were over fit. Therefore, race was not associated with any outcomes independent of any racial differences in pathologic grade group.
Interactions With Race
By using a P value threshold of .0033, the only statistically significant interaction with race was with PSADT for predicting metastases (P = .002), because PSADT was a stronger predictor of metastases among CM (P < .001) than among AAM (P = .016). No other interactions were statistically significant (Table 3) .
DISCUSSION
Although it is known that AAM have higher PC incidence and mortality rates compared with CM, [1] [2] [3] [4] the exact steps in the clinical setting of PC (diagnosis, progression after primary treatment, progression after secondary treatment, etc) that drive these health disparities are not clear. In the current study, we evaluated VA patients who were initiating ADT for a BCR that developed after RP. It is noteworthy (and contrary to our hypothesis) that race was not associated with metastases or any long-term outcome in the current study. Although we observed that PSADT was a stronger predictor of metastases in CM versus AAM, it was associated with metastases in both races. Therefore, the clinical relevance of this observation is not clear. Our results, coupled with other studies from our group demonstrating no differences in long-term outcomes either at the time of RP 6 or at the time of nonmetastatic CRPC, 7 suggest that, to understand PC health disparities, research should focus on why AAM present with a greater risk of more aggressive cancers at the time of diagnosis. Months from ADT CM AAM The multivariable model was adjusted for prostate-specific antigen level at ADT, pathologic Gleason score, pathologic features (seminal vesicle invasion, extracapsular extension, positive surgical margins, lymph node invasion), age at ADT, year of ADT, surgical center, body mass index at ADT, prostate-specific antigen doubling time at ADT, radiation therapy, early biochemical recurrence, time from surgery to ADT, and time from surgery to recurrence). Abbreviations: ACM, all-cause mortality; ADT, androgen-deprivation therapy; BCR, biochemical recurrence; BMI, body mass index; CRPC, castrateresistant prostate cancer; DNC, model did not converge; PCSM, prostate cancer-specific mortality; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time.
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Although our study is the first to examine the impact of race on outcomes after ADT, our null results are in agreement with our previous results among 837 men with CRPC (306 AAM and 531 CM) who had no known metastases (M0/MX), in which AAM and CM were equally likely to be diagnosed with any metastases and had comparable overall survival rates. 7 Similarly, these results are also in agreement with another prior study from the SEARCH database in which we observed that AAM who underwent RP were not at increased risk of aggressive recurrence or the longer term outcomes of metastasis, PCSM, or ACM compared with CM. 6 Because all of our studies were from the VA Health System, which is an equal-access health care system, it is noteworthy that our null results of race and outcomes among men already diagnosed with PC are consistent with other studies of men who received standardized care within a clinical trial setting, whether they received radiation 8 or other therapy for CRPC. 9, 10 These results suggest that, when care is provided equally, whether at an equal-access center or within a clinical trial, race is not associated with outcomes among men diagnosed with PC.
Despite the finding that race does not independently influence outcomes among men diagnosed with PC, AAM continue to present with aggressive PC at a younger ages, leading to an overall increased risk of PC death at the population level. 4 Moreover, a recent study using data from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute to identify 25,445 men aged ≥45 years who were diagnosed with clinically metastatic PC indicated that, as of the year 2013, the incidence of metastatic PC among AAM was almost twice as high compared with the incidence among CM. 11 Given the accumulating research suggesting that race is not a prognostic factor in men diagnosed with PC, research efforts to understand differences by race in PC biology should focus on understanding why AAM present at higher rates than CM with more aggressive disease at diagnosis. 5, 12 Potential causes for more aggressive PC at diagnosis in AAM may include genetics and lifestyle factors. For example, a combination of differences in androgen levels and androgen receptor biology, with dietary factors and lifestyle factors affecting PC carcinogenesis pathways (such as smoking), 13 may lead to an increased risk of aggressive PC in AAM. At the molecular level, 1 study suggested that aggressive PC in AAM may be related to the presence of the Broad11934905 risk allele, which is unique to AAM and is present on chromosome 8q24 (a known PC risk loci). 14 We also observed that several aggressive PC markers, including Ki-67, androgen receptor, and α-methyl-acyl-racemase, were more highly expressed in AAM. 12 Moreover, there are genetic differences in inflammatory-related genes by race. One study demonstrated that AAM had lower expression of Duffy antigen/chemokine receptors (DARCs), such as chemokine (C-X-C motif ) ligand 1 (CXCL1) and CXCL8, on endothelial cells and erythrocytes. 15 DARCs act as a sink for cytokines; therefore, loss of DARC expression leads to higher systemic cytokine levels 16 and then to higher inflammation, which is linked to a greater risk of PC. 17 Finally, others have demonstrated that AAM PCs express higher levels of inflammatory-related genes. 18, 19 All this evidence supports the hypothesis that PC may differ biologically between AAM and CM.
Given the differences in disease biology, we tested whether variables associated with distant metastases differed between AAM and CM on secondary analyses. In general, the same factors were associated with progression in CM and AAM, with 1 exception: PSADT. PSADT was a stronger predictor of metastases in CM versus AAM, although PSADT was associated with metastases in both races. Moreover, there was no significant interaction between race and PSADT for predicting other outcomes, such as CRPC, ACM, or PCSM. Although this interaction was significant after Bonferroni correction, the lack of consistency for the interaction across other measures of disease progression raises questions of a type I error. Therefore, further research is needed to test whether PSADT is indeed more predictive of metastases in CM versus AAM.
Although the current study has several strengths, there are also some limitations, including the retrospective design. This resulted in the exclusion of some men because of missing data. AAM were less likely than CM to be missing covariates, as mentioned above (see Materials and Methods). Part of this is explained because some VA centers have all available data, whereas others do not. How this may have affected our results is unknown; however, all analyses were adjusted for surgical (VA) center, which is linked to race. The numbers of events at metastases, ACM, and PCSM were modest. Thus, the analysis was relatively underpowered, and we cannot exclude a modest association between race and long-term outcomes. Furthermore, given the long natural history of PC and our modest mean follow-up of approximately 5.5 years, it is possible that the results would have differed with longer follow-up and larger sample sizes. The study occurred over a long time. Thus, changes in tumor grading and imaging may have affected our results. However, because these changes would apply equally to AAM and CM, and because we adjusted for year of ADT, it is not clear how these changes would influence the conclusion that there were no differences in long-term outcomes between races. Although we had data on when patients started ADT, we did not have good information on stopping times for ADT; therefore, we assumed that, once patients started ADT treatment, they stayed on it. Furthermore, differences in physician practice could have influenced outcomes. However, most men were managed in an era before modern treatment, including ADT drugs, and these agents were unlikely to have largely influenced our results. Our study only evaluated men undergoing RP and thus represents a selection bias of men who are healthy enough to undergo surgery and excludes men who present with metastatic disease, who are not typically offered surgery. Future studies should address progression endpoints in AAM who receive other treatments, such as radiotherapy. Nonetheless, our approach of analyzing only surgical patients creates a more homogenous cohort in which we can better ask whether men (ie, adjusting for other factors, such as PSA, grade, etc), when treated equally, have equal outcomes. Moreover, our study still represents the largest to date evaluating metastasis and death among AAM who undergo RP and have equal access to care.
In summary, in an equal-access setting of men who received ADT post-BCR after RP, race was not a predictor of metastases or of any other longer term outcome. PSADT was a stronger predictor of metastases in CM versus AAM, although it was predictive of metastases in both races. Thus, future research efforts to understand racial differences in PC biology should focus on understanding why AAM present at higher rates than CM with more aggressive disease at diagnosis.
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